

#9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

John R. HESS *et al.*

Appl. No. 09/756,907

Filed: January 10, 2001

For: COMPOSITIONS FOR
TREATMENT OF
HEMORRHAGING WITH
ACTIVATED FACTOR VLLA IN
COMBINATION WITH
FIBRINOGEN AND METHODS
OF USING SAME



Art Unit: 3614

Examiner: n/a

Atty. Docket No. 38644-170537

Customer No. 6339



26694

PATENT TRADEMARK OFFICE

RECEIVED

APR 02 2002

INFORMATION DISCLOSURE STATEMENT

GROUP 3600

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

This is an Information Disclosure Statement submitted under 37 C.F.R. § 1.97 within the time specified under 37 C.F.R. § 1.97(b), PTO-1449 and copies of references cited therein, listing references reported in the enclosed International Search Report English language family members noted therein.

In order to comply with applicant's duty of disclosure under 37 C.F.R. § 1.56, the U.S. Patent and Trademark Office is notified of the documents which are listed on the attached Form PTO-1449 and which the Examiner may deem relevant to patentability of the claims of the above-identified application. One copy of each of the listed documents is submitted herewith.


The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no Statement Under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In view of the above, no further translation or statement of relevance is required, and as all requirements of 37 C.F.R. § 1.97 and all official guide lines pertaining to Information Disclosure Statements have been complied with, and it is therefore respectfully requested that the Examiner consider the documents and make them of record.

REMARKS

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 22-0261**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,



Thomas G. Wiseman
Registration No. 35,046

Date: March 29, 2002

VENABLE
P.O. Box 34385
Washington, D.C. 20043-9998
Telephone: (202) 962-4800
Telex: (202) 962-8300

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/756,907
Filing Date	January 10, 2001
First Named Inventor	John R. HESS et al.
Group Art Unit	3614
Examiner Name	n/z
Attorney Docket Number	38644-170537

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HEDNER U.: Treatment of patents with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.: THROMOSIS AND HAEMOSTASIS: vol. 82, no. 2, 1999: pages 531-539.	
		SCHMIDT M.L. ET AL.: Recombinant activated factor VII therapy for intracranial hemorrhage in hemophilia A patients with inhibitors: american journal of hematology: vol 47, no. 1, 1994, pages 36-40.	

RECEIVED
APR 02 2002
GROUP 3600

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

VENABLE
ATTORNEYS AT LAW